Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLPHNASDAQ:CEMINASDAQ:LIXTNASDAQ:NRBO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLPHBellerophon Therapeutics$0.01$0.02$0.01▼$0.02$147K0.7418,907 shs7,027 shsCEMIChembio Diagnostics$0.46$0.43$0.19▼$1.24$16.71M1.85661,416 shs351,642 shsLIXTLixte Biotechnology$0.83-25.0%$1.26$0.64▼$3.00$2.23M0.37183,278 shs346,204 shsNRBONeuroBo Pharmaceuticals$0.70+1.2%$0.78$2.08▼$5.30$6.03M-0.2652,006 shs34,797 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLPHBellerophon Therapeutics0.00%0.00%0.00%0.00%-80.46%CEMIChembio Diagnostics0.00%0.00%0.00%0.00%0.00%LIXTLixte Biotechnology-24.98%-32.30%-35.95%-39.44%-66.29%NRBONeuroBo Pharmaceuticals-5.09%-10.71%+1.10%-56.46%-81.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLPHBellerophon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACEMIChembio DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLPHBellerophon Therapeutics 0.00N/AN/AN/ACEMIChembio Diagnostics 0.00N/AN/AN/ALIXTLixte Biotechnology 0.00N/AN/AN/ANRBONeuroBo Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLPHBellerophon Therapeutics$5.64M0.03N/AN/A$0.27 per share0.04CEMIChembio Diagnostics$48.34M0.35N/AN/A$0.48 per share0.95LIXTLixte BiotechnologyN/AN/AN/AN/A($1.19) per shareN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/A$1.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/AN/AN/AN/ACEMIChembio Diagnostics-$23.29M-$1.20N/A∞N/A-47.03%-113.57%-38.22%N/ALIXTLixte Biotechnology-$3.59M-$1.45N/A∞N/AN/AN/A-189.35%8/6/2025 (Estimated)NRBONeuroBo Pharmaceuticals-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%8/12/2025 (Estimated)Latest NRBO, CEMI, BLPH, and LIXT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025LIXTLixte BiotechnologyN/A-$0.29N/A-$0.29N/AN/A3/24/2025Q4 2024LIXTLixte BiotechnologyN/A-$0.27N/A-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLPHBellerophon TherapeuticsN/AN/AN/AN/AN/ACEMIChembio DiagnosticsN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLPHBellerophon TherapeuticsN/AN/AN/ACEMIChembio DiagnosticsN/A1.231.04LIXTLixte BiotechnologyN/A4.264.26NRBONeuroBo PharmaceuticalsN/A2.412.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLPHBellerophon Therapeutics10.61%CEMIChembio Diagnostics8.65%LIXTLixte Biotechnology5.10%NRBONeuroBo Pharmaceuticals1.37%Insider OwnershipCompanyInsider OwnershipBLPHBellerophon Therapeutics5.20%CEMIChembio Diagnostics3.30%LIXTLixte Biotechnology14.80%NRBONeuroBo Pharmaceuticals1.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLPHBellerophon Therapeutics2012.23 million11.60 millionNo DataCEMIChembio Diagnostics33736.73 million35.51 millionNot OptionableLIXTLixte Biotechnology42.68 million2.29 millionNot OptionableNRBONeuroBo Pharmaceuticals108.62 million8.53 millionNot OptionableNRBO, CEMI, BLPH, and LIXT HeadlinesRecent News About These CompaniesNeuroBo Pharmaceuticals (NASDAQ:NRBO) Shares Up 3.9% - Should You Buy?June 11, 2025 | americanbankingnews.comMTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…December 4, 2024 | msn.comNeuroBo Pharmaceuticals Rebrands as MetaVia: Strategic Positioning and Growth Potential Highlighted in Buy Rating by Jason McCarthyNovember 21, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals rebrands to become MetaViaNovember 19, 2024 | fiercepharma.comNeuroBo Pharmaceuticals Rebrands Amidst Strategic ChangesNovember 19, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals announces relignment, change nameNovember 19, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic DiseasesNovember 18, 2024 | prnewswire.comNRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024November 13, 2024 | msn.comNeuroBo Pharmaceuticals to Participate in Investor Conferences in NovemberNovember 13, 2024 | prnewswire.comNeuroBo Pharmaceuticals to Present at the November 21st Virtual Investor Summit Microcap EventNovember 12, 2024 | bignewsnetwork.comNeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 7, 2024 | prnewswire.comNeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNovember 4, 2024 | prnewswire.comNeuroBo Pharmaceuticals (NASDAQ:NRBO) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comNRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25…October 2, 2024 | msn.comNeuroBo Pharmaceuticals to Participate in Investor Conferences in OctoberOctober 1, 2024 | prnewswire.comNeuroBo Pharma Announces Positive Results From Phase 1 Trial Of DA-1726 In Obesity TreatmentSeptember 30, 2024 | markets.businessinsider.comWe're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn RateSeptember 30, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesitySeptember 30, 2024 | prnewswire.comNeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | prnewswire.comNRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24…August 21, 2024 | msn.comMedia Sentiment Over TimeNRBO, CEMI, BLPH, and LIXT Company DescriptionsBellerophon Therapeutics NASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Chembio Diagnostics NASDAQ:CEMIChembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.Lixte Biotechnology NASDAQ:LIXT$0.83 -0.28 (-24.98%) Closing price 06/18/2025 03:59 PM EasternExtended Trading$0.79 -0.04 (-4.65%) As of 06/18/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.NeuroBo Pharmaceuticals NASDAQ:NRBO$0.70 +0.01 (+1.16%) As of 06/18/2025NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
